| Literature DB >> 33669102 |
Eliya Farah1, Rami Ali1, Parker Tope1, Mariam El-Zein1, Eduardo L Franco1.
Abstract
(1) Background: Preventive measures taken in response to the coronavirus disease 2019 (COVID-19) pandemic have adversely affected an entire range of cancer-related medical activities. The reallocation of medical resources, staff, and ambulatory services, as well as critical shortages in pharmaceutical and medical supplies have compelled healthcare professionals to prioritize patients with cancer to treatment and screening services based on a set of classification criteria in cancer-related guidelines. Cancer patients themselves have been affected on multiple levels, and addressing their concerns poses another challenge to the oncology community. (2)Entities:
Keywords: COVID-19; cancer care; cancer control; cancer resources; clinical practice guidelines
Mesh:
Year: 2021 PMID: 33669102 PMCID: PMC8025749 DOI: 10.3390/curroncol28020100
Source DB: PubMed Journal: Curr Oncol ISSN: 1198-0052 Impact factor: 3.677
Clinical practice guidelines on cancer care and control pre- and during COVID-19 by province.
| Province | Public Health Agency | Pre-COVID-19 [Reference Number] | During COVID-19 |
|---|---|---|---|
| Alberta | Alberta Health Services | Cancer Guidelines for Health Professionals [ | COVID-19 Scientific Advisory Group Rapid Response Report [ |
| British Columbia | BC Cancer Agency | Cancer Management Guidelines [ | Provincial Clinical Cancer Management Guidelines in Pandemic Situation [ |
| Manitoba | Cancer Care Manitoba | Cancer Management Guidelines [ | COVID-19 Important Information for Health Care Providers Regarding Cancer Patients [ |
| Newfoundland and Labrador | Eastern Health | Cancer Care Guidelines [ | Not Available |
| Nova Scotia | Nova Scotia Health Authority | Cancer Management Guidelines [ | COVID-19 Oncology Protocol [obtained via personal communication] [ |
| Ontario | Ontario Health and Cancer Care Ontario | Cancer Treatments [ | COVID-19 Supplemental Clinical Guidance for Patients with Cancer [ |
| Québec | Ministère de la Santé et des Services sociaux | Recommandations concernant le diagnostic et le traitement du cancer dans les établissements du Québec [ | Directives COVID-19 du ministère de la Santé et des Services sociaux [ |
| Saskatchewan | Saskatchewan Cancer Agency | Clinical Practice Guidelines [ | Not Available |
Yukon, Nunavut, and Northwest Territories, as well as Prince Edward Island did not have enough COVID-19 cases to justify issuing “during COVID-19” CPGs. New Brunswick used other provinces’ CPGs.
Figure 1Concept mapping of search techniques, data collection process, and descriptive components.
Overview by theme of the components and characteristics of Canadian clinical practice guidelines for cancer care and control during the COVID-19 pandemic.
| Theme | Components | Characteristics and Type of Information Provided |
|---|---|---|
|
| Broad-spectrum treatment | General prioritization criteria for anticancer treatment based on risk of tumour progression, as well as treatment form (i.e., adjuvant, curative, neoadjuvant, palliative), performance/symptom status, efficacy, need, age, capacity, comorbidities, and tumour stage, among other factors |
| Cancer-specific treatment | Prioritization criteria for anticancer treatment by cancer site | |
| Radiation-specific treatment | Prioritization criteria to triage patients with cancer to radiation therapy | |
| Systemic-specific treatment | Prioritization criteria to triage patients with cancer to systemic therapy | |
| Surgical-specific treatment | Prioritization criteria to triage patients with cancer to surgical procedures | |
| Palliative-specific care | Prioritization criteria to triage patients with cancer to palliative care (i.e., symptom management, psychosocial support, end of life care) | |
| Treatment for newly diagnosed patients | Guidelines and/or recommendations to manage treatments for newly diagnosed patients with cancer | |
| Treatment delay | Estimated wait time (days, weeks, or months) to target treatment (i.e., systemic, surgery, radiation therapy) particular to each prioritization level | |
|
| Broad-spectrum screening | General prioritization criteria for screening procedures based on form (i.e., diagnostic, routine, genetic, follow-up) and type (i.e., CT scan, MRI, mammogram) of screening procedure, as well as screening urgency to diagnose and/or treat, among other factors |
| Routine-specific screening | Prioritization criteria to triage individuals to routine screening procedures (i.e., mammograms, Pap smear tests, HPV tests) | |
| Diagnostic imaging | Prioritization criteria to triage individuals to diagnostic imaging procedures (i.e., computed tomography, magnetic resonance imaging, positron emission tomography) | |
| Genetic screening | Prioritization criteria to triage individuals to genetic screening procedures for oncological disorders | |
| Screening delay | Estimated wait time (days, weeks, or months) to screening procedures (i.e., mammograms, Pap smear tests, human papillomavirus tests, computed tomography lung scans) particular to each prioritization level or category | |
|
| General information | Information (i.e., diagnosis, symptoms, treatments, modes of transmission) related to COVID-19 disease and/or SARS-CoV-2 infection |
| Precautionary measures | Information about personal preventive measures (i.e., practicing good hygiene, maintaining physical distancing, wearing masks) and/or departmental mitigation measures (i.e., remote consultations when possible, minimizing additional visitors in waiting rooms) | |
| Treatment management | Guidelines and/or recommendations to manage anticancer treatment procedures for patients with cancer who tested positive for COVID-19 | |
| Screening management | Guidelines and/or recommendations to manage cancer screening operations (i.e., colorectal, cervical, breast cancer screening) for individuals who tested positive for COVID-19 |
Overview by theme of the components and characteristics of Canadian resources for cancer care and control during the COVID-19 pandemic.
| Theme | Components | Characteristics and Type of Information Provided |
|---|---|---|
|
| General information | Public health information about COVID-19 (i.e., definition, symptoms, diagnosis, treatment) and/or links to relevant, external resources |
| Preventive measures | Protective practices related to SARS-CoV-2 (i.e., handwashing, wearing masks, social distancing advice) and/or the meaning of being immunocompromised and at an increased risk of developing worse COVID-19 symptoms compared to healthy individuals | |
| Self-assessment tool | Link(s) to provincial and/or federal online COVID-19 self-assessment tools including online series of inquiries into whether an individual has experienced any COVID-19 symptoms, travelled outside of Canada recently, had close contact with a symptomatic person, and/or travelled recently in the past 14 days | |
| Implications on treatment | Effects of COVID-19 on in-patient and/or out-patient cancer treatments including visitation changes and alterations in treatment timelines and/or information on putative changes to treatment if a patient were to test positive for COVID-19 during treatment | |
| Implications on screening | Effect of the COVID-19 pandemic on access to cancer screening (i.e., regular screening, pre-treatment surveillance, post-treatment screening, self-sampling) | |
|
| Physical health resources | Access to articles, links, and/or webinar series along with professional advice (i.e., oncology-specific nutrition advice) and resources (i.e., exercise webinars) relating to physical health of patients with cancer |
| Financial resources | Internal (i.e., donor-supported financial programs) and/or external financial resources (i.e., links to applications for employment insurance sickness benefits, Canada’s Emergency Response Benefit, donor-sourced financial support, Canada’s COVID-19 Economic Response Plan) for patients with cancer | |
| Mental health resources | Access to articles, external links, lecture series, online support groups, and/or webinars relating to mental health implications (i.e., anxiety, fear, isolation) for patients with cancer and their caregivers |
Checklist of Canadian clinical practice guidelines amid the COVID-19 pandemic by theme, descriptive components, and provincial agencies.
| Provincial Agency | Cancer Care (i.e., Treatment) | Cancer Control (i.e., Screening) | Cancer Care and Control for Patients with COVID-19 | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broad-Spectrum | Cancer-Specific | Radiation-Specific | Systemic-Specific | Surgical-Specific | Palliative-Specific | Newly Diagnosed Patients | Delay | Broad-Spectrum | Routine-Specific | Diagnostic Imaging | Genetic | Delay | General Information | Precautionary Measures | Treatment Management | Screening Management | |
| ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |||||||||
| ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||||
| ✓ | ✓ | ✓ | ✓ | ✓ | |||||||||||||
| ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |||||||||
| ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||
| ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||||
Yukon and the Northwest Territories have not modified their oncological practice, thus their cancer care and control clinical practice guidelines have not been changed. Nunavut operating under the Ottawa-Bafin Island program infers treatment using Ontario cancer guidelines. New Brunswick and Prince Edward Island refers to guidelines issued by other Canadian agencies including Ontario, British Columbia, and Quebec.
Checklist of resources and recommendations amid the COVID-19 pandemic by theme, descriptive components, and organization.
| Society | Knowledge & Awareness | Cancer Care & Control during COVID-19 | Supportive Resources | |||||
|---|---|---|---|---|---|---|---|---|
| COVID-19 Information | SARS-CoV-2 Preventive Measures | Self-Assessment Tool | Implications on Treatment | Implications on Screening | Physical Health Resources | Financial Resources | Mental Health Resources | |
| ✓ | ✓ | ✓ | ✓ | ✓ | ||||
| ✓ | ✓ | |||||||
| ✓ | ✓ | |||||||
| ✓ | ✓ | ✓ | ||||||
| ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |||
| ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||
| ✓ | ✓ | ✓ | ✓ | ✓ | ||||
| ✓ | ✓ | |||||||
| ✓ | ✓ | ✓ | ||||||
| ✓ | ✓ | |||||||
| ✓ | ✓ | ✓ | ✓ | ✓ | ||||
| ✓ | ||||||||
| ✓ | ||||||||
| ✓ | ✓ | ✓ | ||||||
| ✓ | ✓ | ✓ | ✓ | |||||
| ✓ | ✓ | ✓ | ✓ | |||||
| ✓ | ✓ | |||||||
| ✓ | ✓ | ✓ | ✓ | |||||
| ✓ | ✓ | ✓ | ✓ | |||||
| ✓ | ✓ | ✓ | ||||||
| ✓ | ✓ | |||||||
| ✓ | ✓ | |||||||
Of the 187 cancer organizations screened, 22 societies provided COVID-19 information specific to cancer patients. The societies’ webpages were last accessed on 4 November 2020. Hyperlinks were generated for quick access to the COVID-19 information provided by each society.